After reviewing hundreds of FDA submissions from early-stage pharma companies, there's a clear pattern. The same 5 mistakes show up over and over — and they're all preventable.

1. Submitting before your CMC section is airtight. Chemistry, Manufacturing, and Controls is where the FDA looks first. If your manufacturing process isn't fully characterized and documented, expect a Refuse to File letter. Most startups rush this.

2. Ignoring the pre-IND meeting. The FDA literally offers to tell you what they want to see. Yet ~40% of first-time applicants skip it. This single meeting can save you 6-12 months of back-and-forth.

3. Using boilerplate safety language. Copy-pasting safety sections from similar drugs is tempting, but the FDA's reviewers know. Your safety profile needs to be specific to YOUR compound, YOUR formulation, YOUR patient population.

4. Underestimating the eCTD formatting requirements. Electronic Common Technical Document formatting is brutal. One mislinked cross-reference, one improperly paginated module, and your submission gets kicked back before anyone reads the science.

5. No regulatory intelligence on recent FDA trends. The FDA's priorities shift. What got approved 3 years ago might face new scrutiny today. If you're not tracking recent Complete Response Letters and Advisory Committee trends in your therapeutic area, you're flying blind.

We built RegulatoryIQ to catch these exact problems before they cost you time and money. AI-powered compliance checks, real-time regulatory tracking, and submission readiness scoring — all designed for startups navigating FDA for the first time.